HIV Vaccine Trial Participants May Need More Behavior Counseling

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

HIV Vaccine Trial Participants May Need More Behavior Counseling

Reuters Health Information Services (12/17/97)

Abstract: Researchers at the University of California in San Francisco report that HIV vaccine trial participants with histories of high-risk sexual behavior may return to such behavior during the trial if they incorrectly believe they are protected against HIV. In the Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Margaret A. Chesney and colleagues report that they conducted a longitudinal study of 48 HIV-negative men and women who participated in Phase I and II placebo-controlled HIV vaccine trials at San Francisco General Hospital. From their examination, the researchers found an increase in unprotected anal intercourse from 9 percent at trial entry to 20 percent at the 12-month assessment. They also found higher-risk behaviors among younger trial participants, those who had multiple sexual partners, and those who indicated that hope of protection from HIV was one of their reasons for joining the trial. Based upon their findings, the researchers suggest that HIV vaccine trial participants should be carefully screened and should receive more counseling before entering the trials.

971218
AD972319

Copyright © 1997 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.